FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.uv.ebm
Resource TypeEvidenceVariable
IdEvidenceVariable-346495.json
FHIR VersionR6

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: EvidenceVariable 346495

version: 5; Last updated: 2026-01-26 16:43:36+0000

url: EvidenceVariable CTIS2024-516402-32-00 Secondary Outcome 8

identifier: FEvIR Object Identifier/346495, FEvIR Linking Identifier/CTIS2024-516402-32-00 Secondary Outcome 8, CTIS endPoint id/441516, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.24.11

version: 1.0.0-ballot3

name: CTIS2024_516402_32_00_Secondary_Outcome_8

title: CTIS2024-516402-32-00 Secondary Outcome 8

status: Active

date: 2026-03-27 09:54:14+0000

author: Brian S. Alper, MD, MSPH:

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

Costs relating to renal replacement therapy (or lack of), Eculizumab and other antihypertensive treatments, hospitalizations

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

Source1

{
  "resourceType": "EvidenceVariable",
  "id": "346495",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2026-01-26T16:43:36.602Z"
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://fevir.net/resources/EvidenceVariable/346495",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "346495",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "CTIS2024-516402-32-00 Secondary Outcome 8",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "CTIS endPoint id"
      },
      "value": "441516"
    },
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.4.642.40.44.24.11"
    }
  ],
  "version": "1.0.0-ballot3",
  "name": "CTIS2024_516402_32_00_Secondary_Outcome_8",
  "title": "CTIS2024-516402-32-00 Secondary Outcome 8",
  "status": "active",
  "date": "2026-03-27T09:54:14+00:00",
  "author": [
    {
      "name": "Brian S. Alper, MD, MSPH"
    }
  ],
  "publisher": "HL7 International / Clinical Decision Support",
  "contact": [
    {
      "name": "HL7 International / Clinical Decision Support",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "description": "Costs relating to renal replacement therapy (or lack of), Eculizumab and other antihypertensive treatments, hospitalizations",
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/"
}